BMJ  2008;336:1456-1457 (28 June), doi:10.1136/bmj.a451 (published 23 June 2008)

News

Opportunity was missed in choice of cervical cancer vaccine, health campaigners say

Zosia Kmietowicz

1 London

The first 150 words of the full text of this article appear below.

Girls throughout the United Kingdom will receive the human papillomavirus vaccine Cervarix in the national immunisation programme after it launches in September, the Department of Health has said.

Cervarix, which is made by GlaxoSmithKline, offers protection against human papillomavirus types 16 and 18, which are responsible for about 70% of cervical cancers.

In England, 300 000 girls aged 12 to 13 will be given the vaccine in the first year of the programme. In the next two years 1.8 million doses of vaccine will be dispensed for routine and catch-up vaccinations for girls aged 14 to 18.

Dawn Primarolo, the health minister, described the vaccine as "an exciting opportunity" that could save the lives of 400 women a year.

However, sexual health charities have expressed disappointment at the decision not to offer Sanofi Pasteur’s Gardasil in the national programme. Gardasil protects against four types of human papillomavirus (types 6, 11, . . . [Full text of this article]


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

This article has been cited by other articles:

  • Gericke, C. A (2008). Paradox of vaccination in cervical cancer and screening. BMJ 337: a1049-a1049 [Full text]  

Rapid Responses:

Read all Rapid Responses

How can we know if we can't scrutinise the details?
Peter M English
bmj.com, 24 Jun 2008 [Full text]
Re: How can we know if we can't scrutinise the details?
Mark Struthers
bmj.com, 4 Jul 2008 [Full text]
Access jobs at BMJ Careers
Whats new online at Student BMJ